While Europe continues to make progress in approving biosimilar biologics, the US has work to do to keep pace, says Paul Calvo.
Approval of biosimilar biologics continues to be a topic of great interest as the push for accessibility to cheaper biologic medicines continues. Globally, the clear leader in the area is the European Medicines Agency (EMA), with the US Food and Drug Administration (FDA) lagging considerably behind. To look at these contrasting situations, one may think that Europe is taking one step forward, while the US takes two steps back.
The wait for approval of a biosimilar biologic goes on in the US. Since passage of the Patient Protection and Affordable Care Act on March 23, 2010, the FDA has been in the process of implementing an abbreviated licensure pathway for biosimilars. The FDA released several draft guidance documents related to the approval pathway in February 2012.
These guidance documents dealt with (1) scientific considerations in demonstrating biosimilarity to a reference product; (2) quality considerations in demonstrating biosimilarity to a reference protein product; and (3) questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009, aka the Biosimilars Act.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
Biosimilars, biologics, Biosimilars Act, FDA, SB-598